Emerging market opportunities include developing IGF-1R-targeted therapies for thyroid eye disease, leveraging prior success with Tepezza. In oncology, focus on biomarker-driven patient stratification ...

Phase 3 trial data showed elegrobart significantly improved proptosis and diplopia in patients with moderate to severe chronic thyroid eye disease.

Secondary lymphedema occurs when, after surgery or radiotherapy, the lymphatic system cannot drain interstitial fluid effectively, leading to inflammation and fluid accumulation in the limbs. Previous ...

Viridian Therapeutics recently reported positive topline results from its REVEAL‑2 phase 3 trial of elegrobart in chronic thyroid eye disease, while also completing US$125,000,014 of common stock and ...

FOXO3a predicts for survival and its phosphorylated form is downregulated following mTOR or MEK inhibitor therapy in Hepatocellular Carcinoma Performance status 0 (n=42) (vs. PS 2) 0.19 0.05 - 0.72 ...

ROCKVILLIE, MD. and SUZHOU, China, Feb. 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

The type 1 IGF receptor (IGF-IR) is activated by two ligands, IGF-1 and IGF-2, and by insulin at supraphysiological concentrations. It plays a significant role in the growth of normal and abnormal ...

Scientists at Minghui Pharmaceutical (Hangzhou) Ltd. and Minghui Pharmaceutical Inc. have synthesized antibody-drug conjugates comprising a humanized monoclonal antibody targeting insulin-like growth ...

The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population. This is an ASCO Meeting Abstract from the 2012 ASCO ...

In March, Viridian posted a phase 3 win for elegrobart in active TED, defined as patients who developed symptoms within 15 ...